| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5590832 | Multiple Sclerosis and Related Disorders | 2017 | 9 Pages |
Abstract
Data for the high-efficacy DMTs natalizumab and alemtuzumab, and the moderately high-efficacy DMT fingolimod, suggest they are effective in this patient population. Further studies are warranted, and clinical trial data to inform treatment decisions for this high-risk group represent a significant unmet need.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Ãscar Fernández,